AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
== Development roadmap == In Sep 2017, Adobe announced the roadmap anticipating releases in 2018 and 2020. Among the key features anticipated for the 2016 release were a new performance monitor, enhancements to asynchronous programming, revamped REST support, and enhancements to the API Manager, as well as support for CF2016 projected into 2024. As for the 2020 release, the features anticipated at that time (in 2017) were configurability (modularity) of CF application services, revamped scripting and object-oriented support, and further enhancements to the API Manager.
=== Energy collaboration: oil exploration === A central pillar of the agreement is U.S.–Pakistan cooperation to explore and develop Pakistan’s underexplored oil reserves—particularly in offshore Balochistan and onshore regions such as Sindh, Punjab and Khyber Pakhtunkhwa. Trump stated that selecting an oil company to lead this initiative will be done with transparency, adding that “maybe they’ll be selling oil to India someday”. Secondary aspects of the agreement include cooperation in sectors like mining, IT, cryptocurrency, and digital infrastructure.
As indicated by the National Academy of Sciences report Strengthening Forensic Sciences in the United States, part of the problem is that many traditional forensic sciences have never been empirically validated; and part of the problem is that all examiners are subject to forensic confirmation biases and should be shielded from contextual information not relevant to the judgment they make. Studies of rape-related injury prevalence and frequency across race have reported racial differences when studying adult rape victims, with higher percentage of white victims sustaining injuries and/or white victims sustaining a higher number of injuries than Black victims. However, current forensic examination techniques may not be sensitive to all injuries across a range of skin colors. One study found that it was dark skin color, not race, that strongly correlated with decreased injury prevalence, concluding therefore, that sexual assault forensic examiners "may not be able to detect injury in women with dark skin as readily as women with light skin, leading to health disparities for women with dark skin" (Sommers et al., 2009). In clinical practice, for patients with darker skin, one study recommends that attention must be paid to the thighs, labia majora, posterior fourchette and fossa navicularis, so that no rape-related injuries are missed upon close examination.
== Single-player mods == Aperture Tag - A modification based on Portal 2 that recreates the essence of the game Tag: The Power of Paint, the inspiration for the various gels used in Portal 2. Instead of a portal gun, the player solves puzzles using a mix of these gels that they can spray onto surfaces with a tool they carry. Black Mesa - A third-party recreation of Half-Life (1998) that was made in response to the release of Half-Life: Source (2004), a port of the original game to the Source engine. Black Mesa originally released as a free mod in September 2012, and later had a full commercial release on Steam in March 2020. Coastline to Atmosphere - A mod set in the Half-Life 2 universe, following Gordon Freeman after the events of Half-Life 2. Dear Esther - An experimental "ghost story" created as a research project at the University of Portsmouth; initially released as a free modification in 2008, a longer commercial version was developed and released in 2012. Entropy: Zero - A Half-Life 2 modification developed by Breadman set before the base game's story in which a Combine Civil Protection officer, named "Bad Cop", becomes stranded in City 10. Entropy: Zero - Uprising - A mod of Entropy: Zero developed by Employee8 and Filipad that takes place during the uprising in Half-Life 2. Entropy: Zero 2 - A sequel to Entropy: Zero. Set post-Half-Life 2, its story follows Bad Cop, who has been promoted to "Elite" status, as he works to capture Dr. Judith Mossman, the former assistant of Earth's Administrator.
Sources: en.wikipedia.org
==== Marquez: The Wannabe B-Boy ==== Meet Marquez, a street fighter who makes life miserable for twins Richard and Edward. Mayhem brings in Brazilian jiu-jitsu specialist, Quinn Mulhern standing at 6'3 and weighing in at 177 lbs, with a record of 14 wins and 1 loss to put him in his place. This episode has never aired on American TV and is not available on the Bully Beatdown website like most other episodes. The episode has been aired in the Netherlands, the Fox8 channel of Foxtel and Austar in Australia, and MTV Latin America. Many have speculated that the bully winning more money is the reason why it was never broadcast in America.
The activation of the endogenous opioids is for an analgesic effect using the gate control theory of pain. In addition, deep dry may also decrease pain, increase range of motion, and minimize myofascial trigger point irritability. In regards to the factor of pain reduction, relief occurs at four central levels: local pain, spinal pain through nerves, brain stem pain, and higher brain center pain. The relief of myofascial trigger points has been more highly researched than the relief of connective tissues, muscle fascia, muscle tension, and scar tissue; however, the American Physical Therapy Association claims that there potentially may be some benefits of dry needling on these ailments according to some available evidence. The APTA also claims that dry needling should not be used as a standalone procedure, but should be used in conjunction with other treatment methods, including manual soft tissue mobilization, neuromuscular re-education, functional retraining, and therapeutic exercises. Once the needle is inserted, one can manually or electrically stimulate the filiform needle depending for the desired effect of treatment.
The eastern brown snake (Pseudonaja textilis) has a venom LD50 value of 0.053 mg SC (Brown, 1973) and a value of 0.0365 mg SC (Ernst and Zug et al. 1996). Average venom yield is 2–6 mg (Meier and White, 1995). Average venom yield (dry weight) is between 5–10 mg (Minton, 1974). Maximum venom yield for this species is 155 mg. This species is legendary for its bad temper, aggression, and for its speed. This species is responsible for more deaths every year in Australia than any other group of snakes. Australia reports on average well under 10 snake bite deaths per year due to high levels of snake awareness and education, quality medical facilities and personnel and the availability of anti venom.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.